Comparison · NCT03411031-9963a56f
A: Elotuzumab + Lenalidomide at 25 mg vs B: Elotuzumab + Lenalidomide at 10 mg: Overall Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Download JSON
Cite this record
ConductScience Library. A: Elotuzumab + Lenalidomide at 25 mg vs B: Elotuzumab + Lenalidomide at 10 mg: Overall Response. Trial comparisons, record NCT03411031-9963a56f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03411031-9963a56f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.111 | 0.0199 | 0.435 | wilson | |
| Risk in group 2 | 0.222 | 0.0632 | 0.547 | wilson | |
| Risk difference, group 1 minus group 2 | -0.111 | -0.449 | 0.25 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.0545 | 4.58 | log | |
| Odds ratio, group 1 over group 2 | 0.438 | 0.0323 | 5.93 | log | |
| Number needed to treat, for one fewer participant with the outcome on A: Elotuzumab + Lenalidomide at 25 mg than on B: Elotuzumab + Lenalidomide at 10 mg | 9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | A: Elotuzumab + Lenalidomide at 25 mg | Elotuzumab 10 mg/kg intravenously (IV) weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 25 mg by mouth (PO) daily days 1-21 out of a 28-day schedule.~Elotuzumab: Elotuzumab according to dosing schedule outlined in treatment arms.~Lenalidomide: Lenalidomide according to dosing schedule outlined in treatment arms.~Dexamethasone: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert. | 1 | 9 | OG000 |
| Group 2 | B: Elotuzumab + Lenalidomide at 10 mg | Elotuzumab 10 mg/kg IV weekly (days 1, 8, 15 and 22) for 2 cycles, then 20 mg/kg every 4 weeks. Dexamethasone will be administered as premedication for elotuzumab.~Lenalidomide 10 mg PO daily days 1-21 out of a 28-day schedule.~Elotuzumab: Elotuzumab according to dosing schedule outlined in treatment arms.~Lenalidomide: Lenalidomide according to dosing schedule outlined in treatment arms.~Dexamethasone: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert. | 2 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Overall Response
- Description
Overall response with elotuzumab and lenalidomide for each study arm. Overall Response is defined as best Overall Response, as Complete Response or Partial Response. Response will be assessed per the uniform response criteria of the International Myeloma Working Group(IMWG). Myeloma participants enrolled in this clinical study will be assessed for disease response after every cycle. Complete Response= Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates; Partial Response= ≥50% reduction of serum M-protein plus reduction in 24 h urinary M-protein by ≥90% or to \<200 mg per 24 h;
- Time frame
- Up to 60 days post last study treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
- NCT number
- NCT03411031
- Phases
- PHASE2
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Lenalidomide, Dexamethasone
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Results first posted
- 2022-04-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03411031?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03411031-9963a56f